Chimeric antigen receptor T (CAR-T) cell therapy may achieve long-lasting remission in patients with B-cell malignancies not responding to conventional therapies. However, potentially severe and hard-to-manage side effects, including cytokine release syndrome (CRS), neurotoxicity and macrophage activation syndrome, and the lack of pathophysiological experimental models limit the applicability and development of this form of therapy. Here we present a comprehensive humanized mouse model, by which we show that IFN gamma neutralization by the clinically approved monoclonal antibody, emapalumab, mitigates severe toxicity related to CAR-T cell therapy. We demonstrate that emapalumab reduces the pro-inflammatory environment in the model, thus allowing control of severe CRS and preventing brain damage, characterized by multifocal hemorrhages. Importantly, our in vitro and in vivo experiments show that IFN gamma inhibition does not affect the ability of CD19-targeting CAR-T (CAR.CD19-T) cells to eradicate CD19+ lymphoma cells. Thus, our study provides evidence that anti-IFN gamma treatment might reduce immune related adverse effect without compromising therapeutic success and provides rationale for an emapalumab-CAR.CD19-T cell combination therapy in humans.

Manni, S., Del Bufalo, F., Merli, P., Silvestris, D. A., Guercio, M., Caruso, S., Reddel, S., Iaffaldano, L., Pezzella, M., Di Cecca, S., Sinibaldi, M., Ottaviani, A., Quadraccia, M. C., Aurigemma, M., Sarcinelli, A., Ciccone, R., Abbaszadeh, Z., Ceccarelli, M., De Vito, R., Lodi, M. C., Cefalo, M. G., Mastronuzzi, A., De Angelis, B., Locatelli, F., Quintarelli, C., Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies, <<NATURE COMMUNICATIONS>>, 2023; 14 (1): 1-13. [doi:10.1038/s41467-023-38723-y] [https://hdl.handle.net/10807/258554]

Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies

Locatelli, Franco
Penultimo
;
2023

Abstract

Chimeric antigen receptor T (CAR-T) cell therapy may achieve long-lasting remission in patients with B-cell malignancies not responding to conventional therapies. However, potentially severe and hard-to-manage side effects, including cytokine release syndrome (CRS), neurotoxicity and macrophage activation syndrome, and the lack of pathophysiological experimental models limit the applicability and development of this form of therapy. Here we present a comprehensive humanized mouse model, by which we show that IFN gamma neutralization by the clinically approved monoclonal antibody, emapalumab, mitigates severe toxicity related to CAR-T cell therapy. We demonstrate that emapalumab reduces the pro-inflammatory environment in the model, thus allowing control of severe CRS and preventing brain damage, characterized by multifocal hemorrhages. Importantly, our in vitro and in vivo experiments show that IFN gamma inhibition does not affect the ability of CD19-targeting CAR-T (CAR.CD19-T) cells to eradicate CD19+ lymphoma cells. Thus, our study provides evidence that anti-IFN gamma treatment might reduce immune related adverse effect without compromising therapeutic success and provides rationale for an emapalumab-CAR.CD19-T cell combination therapy in humans.
2023
Inglese
Manni, S., Del Bufalo, F., Merli, P., Silvestris, D. A., Guercio, M., Caruso, S., Reddel, S., Iaffaldano, L., Pezzella, M., Di Cecca, S., Sinibaldi, M., Ottaviani, A., Quadraccia, M. C., Aurigemma, M., Sarcinelli, A., Ciccone, R., Abbaszadeh, Z., Ceccarelli, M., De Vito, R., Lodi, M. C., Cefalo, M. G., Mastronuzzi, A., De Angelis, B., Locatelli, F., Quintarelli, C., Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies, <<NATURE COMMUNICATIONS>>, 2023; 14 (1): 1-13. [doi:10.1038/s41467-023-38723-y] [https://hdl.handle.net/10807/258554]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/258554
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
social impact